vaccination

Estimating historical impacts of vaccination against influenza B/Yamagata in the United States to inform possible risks of re-emergence in the absence of vaccination

Influenza B/Yamagata viruses have not been detected globally since 2020 and will be removed from U.S. 2024/25 seasonal influenza vaccines. We inferred impacts of vaccination against B/Yamagata from 2016/17–2019/20 by combining B/Yamagata prevalence …

Estimating historical disease burden and the impact of vaccination by influenza type and subtype in the United States, 2016-2020

Seasonal influenza causes substantial morbidity and mortality in the United States. The U.S. Centers for Disease Control and Prevention (CDC) uses a compartmental framework to estimate the annual disease burden and burden prevented by vaccination for …

Evaluating potential impacts of a preferential vaccine recommendation for adults aged 65 years and older on US influenza burden

**Background**: High-dose, adjuvanted, and recombinant influenza vaccines may offer improved effectiveness among older adults compared to standard-dose, unadjuvanted, inactivated vaccines. However, the Advisory Committee on Immunization Practices …

Vaccine nationalism and the dynamics and control of SARS-CoV-2

Vaccines provide powerful tools to mitigate the enormous public health and economic costs that the ongoing SARS-CoV-2 pandemic continues to exert globally, yet vaccine distribution remains unequal among countries. To examine the potential …

Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes

In the face of vaccine dose shortages and logistical challenges, various deployment strategies are being proposed to increase population immunity levels to SARS-CoV-2. How timing of delivery of the second dose affects infection burden but also …